Table 3.
Adjusted odds ratiosa (aORs) and 95% confidence intervals (CIs) for prescribing vs. not prescribing a drug based on receiving any payment vs. no paymentb
| Drug of Uncertain Medical Benefit | aOR (95%CI) | Brand Control | aOR (95%CI) | Generic Control | aOR (95%CI) |
|---|---|---|---|---|---|
| Lovastatin ER | 1.28 (0.82–2.80) | Rosuvastatin | 1.80 (1.74–1.86) | Lovastatin | 0.78 (0.76–0.80) |
| Almotriptan | 1.36 (0.83–2.23) | Rizatriptan | 0.93 (0.68–1.27) | Sumatriptan | 0.74 (0.50–1.10) |
| Amlodipine+olmesartan | 1.42 (1.36–1.49) | Telmisartan | 1.18 (1.08–1.29) | Irbesartan | 0.74 (0.70–0.78) |
| Ibuprofen+famotidine | 1.10 (0.76–1.60) | Celecoxib | 1.85 (1.80–1.89) | Ibuprofen | 0.79 (0.77–0.81) |
| Saxagliptin+metformin | 1.50 (1.42–1.59) | Sitagliptin | 1.45 (1.42–1.48) | Metformin | 0.80 (0.72–0.89) |
| Naproxen+esomeprazole | 1.45 (1.25–1.68) | Celecoxib | 1.61 (1.57–1.65) | Naproxen | 0.74 (0.72–0.76) |
aAdjusted for gender, specialty, region, therapeutic category and overall prescribing volume
bEach drug was analyzed in a separate model
p-value <0.05 are presented in boldface